Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #603 on Bristol Myers Squibb (BMY)
chmcnfunds
08/16/17 9:19 AM
#604 RE: DewDiligence #603
DewDiligence
09/07/17 9:01 AM
#632 RE: DewDiligence #603
Bristol-Myers Squibb...announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint, demonstrating superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients. The combination also met a secondary endpoint of improved OS versus sunitinib in all randomized patients. Based on a planned interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. …The safety and tolerability of the Opdivo plus Yervoy combination observed in CheckMate-214 was consistent with previous reports of this dosing schedule and similar across subgroups.